Abstract: Due to its heterogeneity, lack of prognostic markers, tumor-escape mechanisms and frequent relapse upon surgical intervention, treatment of hepatocellular carcinoma (HCC) remains challenging. In this issue of Clinical Cancer Research, Groß and colleagues characterize a rodent model, which might help identify novel drugs for combinatorial sorafenib-based therapies for HCC.
Summary
Due to its heterogeneity, lack of prognostic markers, tumor-escape mechanisms and frequent relapse upon surgical intervention, treatment of hepatocellular carcinoma (HCC) remains challenging. In this issue of Clinical Cancer Research, Groß and colleagues characterize a rodent model, which might help identify novel drugs for combinatorial sorafenib-based therapies for HCC.
Research. In 2008, significant progress was achieved when increased survival of patients with advanced HCC was reported following treatment with sorafenib (Nexavar®) in a phase III trial (5) . Based on these studies, stratification of patients that benefit from sorafenib treatment (6) was initiated, and a mechanism of sorafenib resistance in liver cancer (7) was identified. It is expected that improved patient stratification, as well as combinatorial treatments, might enhance the efficacy of sorafenib. Another challenge for the development of HCC treatment is the substantial degree of tumor heterogeneity, present not only within the tissue, but also on an intra-tumoral level (8) .
Another limitation is the lack of suitable pre-clinical rodent models in which to test mono-or combinatorial treatments. Ideally, pre-clinical models should faithfully 
reflect the complexity and heterogeneity of human pathology. Several rodent HCC models recapitulate features of chronic liver disease caused by chronic inflammation, genotoxic (9) or metabolic stress (10, 11) . However, it has become apparent that most rodent models reflect in most cases "only" particular features found in certain subtype(s) of human HCC -and that treatment success in these models does not necessarily correlate with successful translation to the clinics. Thus, existing as well as future rodent models have to be stratified more thoroughly on histological, genetic and molecular levels, as well as for their responsiveness to different treatments.
Moreover, these parameters have to be correlated with human HCC in order to identify which human HCC subtype they most closely resemble, and for which treatments they could be used as a pre-clinical model.
In the current study, Groß and colleagues induce HCC in rats using two different methods: one induced by di-ethyl-nitrosamine (DEN), and the other induced by orthotopically implanted (McA) rat HCC (Fig. 1) . Based on histology, genetic analyses and multimodal imaging, they found liver damage only in DEN-treated rats. 
get a realistic assessment of the applicability of each rodent models. Moreover, the outcome of ongoing and completed clinical trials with human HCC patients using sorafenib combination therapy should be compared to the DEN rat model. Similar responses in the DEN rat model and human trials would further validate the human relevance of this model. Moreover, the mouse DEN model should also be investigated, given its amenability to gene manipulation and responsiveness to sorafenib (12) . In summary, this study underlines that stratification and comparison of rodent models with human HCC is important in order to validate their applicability, although this might be difficult in most cases and may never fit perfectly to a particular human subtype. Importantly, this study also shows that treatment response can be a critical stratification criterion, potentially providing a basis for future validation experiments (e.g., combinatorial treatment) -that ultimately might be more clinically relevant.
Thus, the study by Groß and colleagues is an important first step in establishing and identifying useful pre-clinical rodent models for HCC research.
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